100 results
Page 2 of 5
8-K
EX-99.1
zxkqi5f qok
5 Jun 23
Results of Operations and Financial Condition
8:05am
424B5
t3lhn
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
qs49zinw8yhb 8qhgov
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
q4jw9yb5
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
po9x9
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
u31t4b
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
424B5
n738 pne6w83qqfpva
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
qfuil 91by0hykg59
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.1
aussbrtm7j3psfw 9zcv
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.2
60gwvw n04xnv
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
e0zh4ygsdklsyw5a
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.1
cotv uxoo40ehvhq
4 Aug 22
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
4:17pm
8-K
oi0oba
16 Jun 22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
7:14am
8-K
EX-99.1
2p3xwcyl3ao7her
16 Jun 22
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
7:14am
424B5
bphzf
16 Jun 22
Prospectus supplement for primary offering
6:52am
8-K
EX-99.1
juzweo708c 2jg590
8 Jun 22
Regulation FD Disclosure
9:06am